Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor- agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONSHOHOCKEN, PA., JULY 30, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES.

MADRIGAL PHARMACEUTICALS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

CONSHOHOCKEN, PA., JULY 21, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON JULY 15, 2026 TO TEN NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

MADRIGAL PHARMACEUTICALS ANNOUNCES GRANTS OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

CONSHOHOCKEN, PA., JULY 16, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) ANNOUNCED TODAY THAT IT WILL RELEASE ITS SECOND-QUARTER 2026 FINANCIAL RESULTS ON THURSDAY, JULY 30, 2026, PRIOR TO THE OPEN OF THE U.S. FINANCIAL MARKETS.

MADRIGAL PHARMACEUTICALS TO RELEASE SECOND-QUARTER 2026 FINANCIAL RESULTS AND HOST WEBCAST ON JULY 30, 2026

RECEIVED TWO NEW U.S. REZDIFFRA  (RESMETIROM) PATENTS IN F2/F3; BOTH PATENTS WILL BE LISTED IN THE FDA'S ORANGE BOOK RECEIVED NEW U.S. RESMETIROM PATENT DIRECTED TO A METHOD OF ADMINISTERING RESMETIROM TO TREAT WELL-COMPENSATED CIRRHOSIS (F4C) CONSHOHOCKEN, PA., JULY 13, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) ISSUED THREE NEW RESMETIROM PATENTS.

MADRIGAL PHARMACEUTICALS ANNOUNCES THREE NEW RESMETIROM PATENTS, STRENGTHENING IP PORTFOLIO

CONSHOHOCKEN, PA., JULY 06, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON JULY 1, 2026 TO SEVEN NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SUZHOU, CHINA AND MLNDAL, SWEDEN, JULY 1, 2026 /PRNEWSWIRE/ -- SUZHOU RIBO LIFE SCIENCE CO., LTD. (06938.HK), AND ITS SUBSIDIARY RIBOCURE PHARMACEUTICALS AB (COLLECTIVELY REFERRED TO AS "RIBO"), IN COLLABORATION WITH MADRIGAL PHARMACEUTICALS, INC. (MADRIGAL, NASDAQ: MDGL) ANNOUNCE THE SUCCESSFUL ACHIEVEMENT OF THE FIRST CANDIDATE DRUG NOMINATION MILESTONE WITHIN THEIR SIRNA PARTNERSHIP.

RIBO AND MADRIGAL REACH FIRST MAJOR MILESTONE IN ADVANCING NOVEL SIRNA THERAPIES FOR MASH

CONSHOHOCKEN, PA., JUNE 22, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON JUNE 15, 2026 TO FIVE NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., JUNE 04, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON JUNE 1, 2026 TO 20 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., JUNE 03, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE 47TH ANNUAL GLOBAL GOLDMAN SACHS HEALTH CARE CONFERENCE 2026 ON WEDNESDAY, JUNE 10, 2026, AT 11:20 A.M.

MADRIGAL PHARMACEUTICALS TO PARTICIPATE IN THE 47TH ANNUAL GLOBAL GOLDMAN SACHS HEALTH CARE CONFERENCE 2026

GROWING BODY OF CLINICAL AND REAL-WORLD EVIDENCE SUPPORTS THE ROLE OF REZDIFFRA  (RESMETIROM) AS THE FOUNDATIONAL THERAPY FOR PATIENTS WITH MASH REZDIFFRA IMPROVED ATHEROGENIC LIPID PROFILES ASSOCIATED WITH CARDIOVASCULAR RISK , INCLUDING LDL-C, APOB AND LP(A), IN A SECONDARY ANALYSIS FROM THE PHASE 3 MAESTRO PROGRAM IN PATIENTS WITH WELL-COMPENSATED MASH CIRRHOSIS (F4C), REZDIFFRA IMPROVED A RISK SCORE  ANTICIPATE-NASH  THAT PREDICTS THE PROBABILITY OF EXPERIENCING SEVERE LIVER-RELATED EVENTS MULTIPLE REAL-WORLD ANALYSES EVALUATING THE USE OF REZDIFFRA IN ROUTINE CLINICAL PRACTICE DEMONSTRATED EARLY AND SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC PARAMETERS, LIVER-RELATED BIOMARKERS, AND LIVER STIFFNESS MEASUREMENTS; 49% OF PATIENTS ACHIEVED 25% REDUCTION IN LIVER STIFFNESS OVER A NINE-MONTH FOLLOW-UP PERIOD CONSHOHOCKEN, PA., MAY 27, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED NEW ANALYSES OF PHASE 3 DATA AND REAL-WORLD EVIDENCE DEMONSTRATING REZDIFFRA REDUCED MARKERS OF CARDIOVASCULAR AND LIVER-RELATED RISK IN PATIENTS WITH MASH.

Madrigal Pharmaceuticals, Inc.

MDGL

Price

Financial Reports

No items found.

Press Releases

Madrigal Pharmaceuticals, Inc.

MDGL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MDGL